Search

Your search keyword '"Glioblastomas -- Care and treatment"' showing total 312 results

Search Constraints

Start Over You searched for: Descriptor "Glioblastomas -- Care and treatment" Remove constraint Descriptor: "Glioblastomas -- Care and treatment"
312 results on '"Glioblastomas -- Care and treatment"'

Search Results

52. Studies Conducted at Cleveland Clinic on One-Carbon Group Transferases Recently Reported (Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O-6-Methylguanine DNA Methyltransferase Status in Patients with Glioblastoma)

54. Antioxidant and anticancer activities of extract of Inula helenium (L.) in human U-87 MG glioblastoma cell line

55. Aivita Biomedical gets US FDA nod to begin phase II trial of ROOT OF CANCER technology in patients with glioblastoma multiforme

56. Research from German Cancer Research Center Yields New Findings on Biomarkers [Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) ...]

57. Investigators from University of California Have Reported New Data on Glioblastomas (Tumor treating fields: a new approach to glioblastoma therapy)

58. Findings in the Area of Alkylating Agents Reported from Mayo Clinic (Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02)

59. Studies from University of Alexandria Further Understanding of Glioblastomas (Management of Glioblastoma Multiforme in a Patient Treated With Ketogenic Metabolic Therapy and Modified Standard of Care: A 24-Month Follow-Up)

60. New Glioblastomas Findings from Dana-Farber Cancer Institute Described (Phase 2 and Biomarker Study of Trebananib, an Angiopoietin-Blocking Peptibody, With and Without Bevacizumab for Patients With Recurrent Glioblastoma)

62. Personalized Treatment of Glioblastoma Via Image-Guided Predictive Modeling of Recurrence: A Single-Arm, Single Institutional Pilot Prospective Study of Dose-Escalated Radiation Therapy

63. FDA grants Amgen glioblastoma treatment orphan status

64. Study Results from Tel Aviv Sourasky Medical Center in the Area of Glioblastomas Reported [Short delay in initiation of radiotherapy for patients with glioblastoma- effect of concurrent chemotherapy: a secondary analysis from the NRG ...]

65. Kazia granted orphan status for glioblastoma treatment

66. New Glioblastomas Data Have Been Reported by Researchers at Vanderbilt University (Utilization of hypofractionated radiotherapy in treatment of glioblastoma multiforme in elderly patients not receiving adjuvant chemoradiotherapy: A National ...)

67. New Cytokines Findings Reported from Central South University (Novel Therapy for Glioblastoma Multiforme by Restoring LRRC4 in Tumor Cells: LRRC4 Inhibits Tumor-Infitrating Regulatory T Cells by Cytokine and Programmed Cell Death 1-Containing ...)

69. Enhanced antitumor effects of radiotherapy combined local nimustine delivery rendezvousing with oral temozolomide chemotherapy in glioblastoma patients

70. Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECT Glioblastoma Trial

71. First Patient Enrolled in Novocures Global Phase 3 TRIDENT Trial of Optune Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma

72. First Patient Enrolled in Novocure's Global Phase 3 TRIDENT Trial of Optune[R] Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma

75. AIVITA Biomedical's Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival

76. AIVITA Biomedical's Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival

77. Plus Therapeutics Announces Initiation of Final Cohort of ReSPECT Glioblastoma Trial

78. Plus Therapeutics Announces Initiation of Final Cohort of ReSPECT(TM) Glioblastoma Trial

79. TRACON Announces FDA Orphan Drug Designation for TRC102 in Malignant Glioma, Including Glioblastoma

80. TRACON Announces FDA Orphan Drug Designation for TRC102 in Malignant Glioma, Including Glioblastoma

81. New Data Supports iCAD's Xoft Brain IORT as Feasible Treatment for Recurrent Glioblastoma

82. New Data Supports iCADs Xoft Brain IORT as Feasible Treatment for Recurrent Glioblastoma

83. New Data Supports iCAD's Xoft Brain IORT as Feasible Treatment for Recurrent Glioblastoma

84. ERC-USA Announces Expansion of Glioblastoma Right-to-Try Treatment for ERC1671 with NYU Winthrop Hospital

85. ERC-USA Announces Expansion of Glioblastoma Right-to-Try Treatment for ERC1671 with NYU Winthrop Hospital

86. BerGenBio ASA: BERGENBIO ANNOUNCES FIRST PATIENT DOSED IN RECURRENT GLIOBLASTOMA INVESTIGATOR SPONSORED PHASE I|II STUDY ASSESSING SELECTIVE AXL INHIBITOR BEMCENTINI

87. Bergenbio Announces First Patient Dosed in Recurrent Glioblastoma Investigator Sponsored Phase I|II Study Assessing Selective AXL Inhibitor Bemcentinib

88. Bergenbio Announces First Patient Dosed in Recurrent Glioblastoma Investigator Sponsored Phase I|II Study Assessing Selective AXL Inhibitor Bemcentinib

90. MediciNova Announces Positive Preclinical Results Regarding MN-166 (ibudilast) in Glioblastoma (GBM) Published in Frontiers in Immunology

91. MediciNova Announces Positive Preclinical Results Regarding MN-166 (ibudilast) in Glioblastoma (GBM) Published in Frontiers in Immunology

92. Ziopharm Oncology Completes Enrollment of Phase 2 Trial Evaluating Controlled IL-12 in Combination with Libtayo(R) in Patients with Glioblastoma

93. GMB RESPONDS TO TRANSPORT SELECT COMMITTEE REPORT INTo BRITISH AIRWAYS TREATMENT OF STAFF; The report has confirmed that British Airways are behaving in a deeply opportunistic way

94. Karyopharm Announces Dosing of First Patient in a Phase 1|2 Study of Selinexor in Combination with Standard of Care Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma

95. Karyopharm Announces Dosing of First Patient in a Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma

96. NW Bio Provides Update On Projected Timing For Data Lock For Phase 3 Trial of DCVax-L for Glioblastoma Brain Cancer

97. NW Bio Provides Update On Projected Timing For Data Lock For Phase 3 Trial of DCVax(r)-L for Glioblastoma Brain Cancer

98. INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12 Months Following Treatment

99. INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo(R) (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12 Months Following Treatment

100. China NMPA Approves Optune for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

Catalog

Books, media, physical & digital resources